We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.91%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$196M
Cap. Flow
+$54.1M
Cap. Flow %
4.71%
Top 10 Hldgs %
49.21%
Holding
84
New
12
Increased
28
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.9M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$38.9M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$18M
4
KND
Kindred Healthcare
KND
+$12.2M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$12.1M

Top Sells

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$33.9M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$19.1M
3
IPXL
Impax Laboratories, Inc.
IPXL
+$15.6M
4
NTUS
Natus Medical Inc
NTUS
+$13.7M
5
CEMP
Cempra, Inc.
CEMP
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 83.26%
2 Consumer Discretionary 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDQ
51
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.18M 0.45%
311,403
+116,386
+60% +$1.66M
IRMD icon
52
iRadimed
IRMD
$1.21B
$4.66M 0.4%
360,884
-50,000
-12% -$432K
QLTI
53
DELISTED
QLT Inc
QLTI
$4.59M 0.4%
1,145,527
– –
RXDX
54
DELISTED
Ignyta, Inc.
RXDX
$4.4M 0.38%
641,700
+416,700
+185% +$2.83M
ADMA icon
55
ADMA Biologics
ADMA
$1.92B
$4.35M 0.38%
+389,193
New +$4.45M
SCTL
56
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.04M 0.35%
1,576,089
+269,092
+21% +$681K
NGNE icon
57
Neurogene
NGNE
$696M
$3.99M 0.35%
26,588
+1,063
+4% +$151K
HZNP
58
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.87M 0.34%
300,000
+298,000
+14,900% +$3.73M
CASC
59
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.8M 0.33%
333,333
+83,333
+33% +$904K
AFAM
60
DELISTED
Almost Family Inc
AFAM
$3.73M 0.32%
128,841
-95,389
-43% -$2.68M
HTWR
61
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$3.67M 0.32%
+50,000
New +$3.8M
DRRX
62
DELISTED
DURECT Corp
DRRX
$3.48M 0.3%
440,450
– –
MRTX
63
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.42M 0.3%
184,756
– –
RDHL
64
Redhill Biopharma
RDHL
$3.85M
$3.35M 0.29%
252
-11
-4% -$114K
CASM
65
DELISTED
CAS Medical Systems, Inc.
CASM
$3.17M 0.28%
1,918,296
– –
AEGR
66
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.14M 0.27%
+150,000
New +$3.78M
TNXP icon
67
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
ANTH
68
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.82M 0.25%
222,977
+60,274
+37% +$875K
MASI
69
DELISTED
Masimo
MASI
$2.58M 0.22%
+97,900
New +$2.42M
AKTX
70
Akari Therapeutics
AKTX
$15.2M
$2.26M 0.2%
59
– –
AMRN
71
Amarin Corp
AMRN
$284M
$2.19M 0.19%
+111,687
New +$2.32M
PHIO icon
72
Phio Pharmaceuticals
PHIO
$12.1M
$1.8M 0.16%
2
– –
ALBO
73
DELISTED
Albireo Pharma Inc
ALBO
$1.77M 0.15%
44,334
– –
PGNX
74
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.51M 0.13%
+200,000
New +$1.2M
RPTP
75
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$164K 0.01%
+15,558
New +$152K
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Broadfin Capital held 84 positions worth $1.15B, up 21% from $954M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Broadfin Capital deployed $54.1M of net new capital in Q4 2014, opening 12 new positions and adding to 28 existing holdings. Its largest new stake was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the largest reduction was AMAG Pharmaceuticals, an estimated $33.9M trimmed.

  • Broadfin Capital's largest Q4 2014 buy was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $47.9M increase.
  • Broadfin Capital's biggest Q4 2014 reduction was AMAG Pharmaceuticals, cutting an estimated $33.9M.
  • Broadfin Capital fully exited Tetraphase Pharmaceuticals, Inc. in Q4 2014, selling an estimated $19.1M.
  • Broadfin Capital's ten largest holdings make up 49% of its $1.15B portfolio in Q4 2014.
  • Broadfin Capital opened 12 new positions and closed 9 in Q4 2014.
  • Broadfin Capital's portfolio value rose 21% quarter-over-quarter to $1.15B.

Based on Broadfin Capital's 13F filing for Q4 2014, filed 17 Feb 2015.